Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.78 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.78 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.78 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.78 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.64 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373802 | 0.88 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28825919 | 0.85 | TGFBR1 (0.82) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5138092 | 0.84 | TGFBR1 (0.75) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7590309 | 0.83 | TGFBR1 (0.78) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4084904 | 0.83 | TGFBR1 (0.84) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5139175 | 0.82 | TGFBR1 (0.79) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL373248 | 0.82 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4154047 | 0.82 | TGFBR1 (0.89) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| Sb-431542 SCHEMBL29432843 | 0.79 | TGFBR1 (0.98) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| Sb-431542 SCHEMBL2681356 | 0.79 | TGFBR1 (0.98) | TGFBR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | TGFBR1 157/4885MAPK14 306/4885MAPK13 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.